• Je něco špatně v tomto záznamu ?

The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy

T. Szarvas, A. Csizmarik, M. Váradi, T. Fazekas, A. Hüttl, P. Nyirády, B. Hadaschik, V. Grünwald, S. Tschirdewahn, SF. Shariat, S. Sevcenco, A. Maj-Hes, G. Kramer

. 2021 ; 39 (5) : 296.e11-296.e19. [pub] 20201009

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004429

OBJECTIVES: The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy. Here, we aimed to test this finding in an independent patient cohort and in addition to explore the prognostic potential of serum MMP-7 in abiraterone (ABI) or enzalutamide (ENZA) treated patients. METHODS AND MATERIALS: MMP-7 levels were measured in 836 serum samples from 320 mCRPC patients collected before and during DOC (n = 95), ABI (n = 140), or ENZA (n = 85) treatment by using the ELISA method. Results were correlated with clinical and follow-up data. RESULTS: MMP-7 baseline levels were similar between the 3 treatment groups. In the ABI and ENZA cohorts, baseline MMP-7 levels were lower in patients with prior radical prostatectomy (P = 0.058 and P = 0.041, respectively). Baseline MMP-7 levels above the median were associated with shorter overall survival for the DOC (P = 0.001) and ENZA (P = 0.006) cohorts. Multivariable analyses in the DOC and ENZA cohorts revealed that high pretreatment MMP-7 level is an independent risk factor for patients' survival. In addition, in DOC-treated patients with high baseline MMP-7 level, marker decrease at the third DOC cycle was associated with improved survival. Patients with high baseline MMP-7 levels had better survival when treated with ABI compared to DOC or ENZA. CONCLUSIONS: We confirmed the prognostic value of pretreatment MMP-7 serum level and its changes as independent predictors of survival in DOC-treated mCRPC patients. In addition, high MMP-7 was a negative predictor in ENZA-treated but not in ABI-treated patients. These results warrant further research to confirm the predictive value of serum MMP-7 and to explore the potential mechanistic involvement of MMP-7 in DOC and ENZA resistance of mCRPC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004429
003      
CZ-PrNML
005      
20220127145244.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2020.09.005 $2 doi
035    __
$a (PubMed)33046366
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Szarvas, T $u Department of Urology, Semmelweis University, Budapest, Hungary; Department of Urology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany. Electronic address: sztibusz@gmail.com
245    14
$a The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy / $c T. Szarvas, A. Csizmarik, M. Váradi, T. Fazekas, A. Hüttl, P. Nyirády, B. Hadaschik, V. Grünwald, S. Tschirdewahn, SF. Shariat, S. Sevcenco, A. Maj-Hes, G. Kramer
520    9_
$a OBJECTIVES: The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy. Here, we aimed to test this finding in an independent patient cohort and in addition to explore the prognostic potential of serum MMP-7 in abiraterone (ABI) or enzalutamide (ENZA) treated patients. METHODS AND MATERIALS: MMP-7 levels were measured in 836 serum samples from 320 mCRPC patients collected before and during DOC (n = 95), ABI (n = 140), or ENZA (n = 85) treatment by using the ELISA method. Results were correlated with clinical and follow-up data. RESULTS: MMP-7 baseline levels were similar between the 3 treatment groups. In the ABI and ENZA cohorts, baseline MMP-7 levels were lower in patients with prior radical prostatectomy (P = 0.058 and P = 0.041, respectively). Baseline MMP-7 levels above the median were associated with shorter overall survival for the DOC (P = 0.001) and ENZA (P = 0.006) cohorts. Multivariable analyses in the DOC and ENZA cohorts revealed that high pretreatment MMP-7 level is an independent risk factor for patients' survival. In addition, in DOC-treated patients with high baseline MMP-7 level, marker decrease at the third DOC cycle was associated with improved survival. Patients with high baseline MMP-7 levels had better survival when treated with ABI compared to DOC or ENZA. CONCLUSIONS: We confirmed the prognostic value of pretreatment MMP-7 serum level and its changes as independent predictors of survival in DOC-treated mCRPC patients. In addition, high MMP-7 was a negative predictor in ENZA-treated but not in ABI-treated patients. These results warrant further research to confirm the predictive value of serum MMP-7 and to explore the potential mechanistic involvement of MMP-7 in DOC and ENZA resistance of mCRPC patients.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a androsteny $x terapeutické užití $7 D000736
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a benzamidy $x terapeutické užití $7 D001549
650    _2
$a docetaxel $x terapeutické užití $7 D000077143
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matrixová metaloproteinasa 7 $x krev $7 D020783
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nitrily $x terapeutické užití $7 D009570
650    _2
$a fenylthiohydantoin $x terapeutické užití $7 D010669
650    _2
$a prognóza $7 D011379
650    _2
$a nádory prostaty rezistentní na kastraci $x krev $x farmakoterapie $x mortalita $7 D064129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Csizmarik, A $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Váradi, M $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Fazekas, T $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Hüttl, A $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Nyirády, P $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Hadaschik, B $u Department of Urology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
700    1_
$a Grünwald, V $u Department of Urology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
700    1_
$a Tschirdewahn, S $u Department of Urology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
700    1_
$a Shariat, S F $u Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Sevcenco, S $u Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
700    1_
$a Maj-Hes, A $u Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
700    1_
$a Kramer, G $u Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 39, č. 5 (2021), s. 296.e11-296.e19
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33046366 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145240 $b ABA008
999    __
$a ok $b bmc $g 1751794 $s 1155578
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 5 $d 296.e11-296.e19 $e 20201009 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20220113
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace